Sol-Gel Technologies (SLGL) Net Income towards Common Stockholders (2017 - 2026)

Sol-Gel Technologies' (SLGL) quarterly Net Income towards Common Stockholders came in at $3.7 million in Q1 2026, down 57.69% year-on-year from $8.8 million in Q1 2025, and up 106.02% on a QoQ basis from -$61.9 million in Q4 2025.

Sol-Gel Technologies (SLGL) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends

Sol-Gel Technologies (SLGL) has 10 years of Net Income towards Common Stockholders data on file, last reported at $3.7 million in Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 57.69% year-over-year to $3.7 million in Q1 2026; TTM through Mar 2026 was -$53.2 million, a 15.04% decrease from a year earlier, with the FY2025 full-year figure at -$66.0 million, down 6.86% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at $3.7 million, up from -$61.9 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for SLGL reached as high as $11.2 million in Q2 2025 and fell as low as -$61.9 million in Q4 2025.
  • Historically, Net Income towards Common Stockholders has averaged -$10.6 million across 5 years, with a median of $134000.0 in 2022.
  • Across the five-year window, Net Income towards Common Stockholders tumbled 8344098460.66% in 2022 and surged 4355.22% in 2023, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$50.9 million in 2022, then slipped by 4.75% to -$53.3 million in 2023, then retreated by 4.82% to -$55.9 million in 2024, then decreased by 10.78% to -$61.9 million in 2025, then jumped by 106.02% to $3.7 million in 2026.
  • Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $3.7 million in Q1 2026, -$61.9 million in Q4 2025, and -$6.3 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -625.73
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -0.68
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 472.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - -453.82 Mn
10 Sol-Gel Technologies 226.64 Mn 216.50 Mn - 3.73 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 3.73 Mn
Dec 31, 2025 -61.92 Mn
Sep 30, 2025 -6.29 Mn
Jun 30, 2025 11.23 Mn
Mar 31, 2025 8.81 Mn
Dec 31, 2024 -55.89 Mn
Sep 30, 2024 -828,000.00
Jun 30, 2024 1.62 Mn
Mar 31, 2024 6.34 Mn
Dec 31, 2023 -53.32 Mn
Sep 30, 2023 -5.71 Mn
Jun 30, 2023 5.97 Mn
Mar 31, 2023 10.72 Mn
Dec 31, 2022 -50.90 Mn
Sep 30, 2022 -0.15
Jun 30, 2022 134,000.00
Mar 31, 2022 5.60 Mn
Dec 31, 2021 0.61
Sep 30, 2021 0.06
Jun 30, 2021 8.03 Mn